Synergistic Integration of Near IR, Closed Chain, Sulfo-Cyanine Dyes and Prostate Specific Membrane Antigen Ligands with Emerging Technologies

The present inventive concept integrates near IR, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands with emerging technologies such as AI, IoT, blockchain, and microfluidics to create a novel system for visualizing, detecting, and treating prostate cancer, enabling real-time image analysis, personalized medicine, and targeted therapy.

The original patent disclosed compositions of near IR, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands for minimally invasive medical techniques. However, the patent's limitations included the lack of integration with emerging technologies, which limited its potential for real-time image analysis, personalized medicine, and targeted therapy. The present inventive concept addresses these limitations by synergistically combining the patented compositions with AI, IoT, blockchain, and microfluidics to create a more powerful system.

The inventive concept comprises a near IR, closed chain, sulfo-cyanine dye and a prostate specific membrane antigen ligand, which are integrated with emerging technologies such as AI, IoT, blockchain, and microfluidics. The AI module enables real-time image analysis, while the IoT-enabled imaging device facilitates remote monitoring and data collection. The blockchain-based tracking system ensures secure and transparent patient data management. The microfluidic device enables controlled release of the fusion compound, allowing for targeted therapy. The inventive concept can be implemented in various formats, including oral and injectable dosage forms, and can be tailored to individual patients' genetic profiles using 3D-printed implants.

The inventive concept's novelty lies in the synergistic integration of the patented compositions with emerging technologies, which enables real-time image analysis, personalized medicine, and targeted therapy. The inventive step lies in the unexpected combination of these technologies, which creates a more powerful system for visualizing, detecting, and treating prostate cancer.

Alternative embodiments of the inventive concept include using different types of dyes, ligands, or emerging technologies. Variations of the inventive concept include using the system for detecting and treating other types of cancer, or integrating the system with other medical devices and platforms.

The inventive concept has significant commercial potential in the medical device and pharmaceutical industries, particularly in the areas of cancer diagnosis and treatment. The target market includes hospitals, clinics, and research institutions, as well as patients and healthcare providers.